San Diego-based biotech company Diomics announced Thursday that it has been awarded more than $2 million in funding from the Department of Defense to develop a transdermal skin patch that will indicate when a person has mounted an immune response to SARS-CoV-2, the virus that causes COVID-19. … Diomics says the Diocheck system is currently entering preclinical animal studies at UC Irvine, with human clinical trials expected to begin in December.
San Diego’s Diomics wins $2M from DoD for COVID-warning skin patch
Times of San Diego, Sept. 18, 2020
September 18, 2020